A Comparison of the Burden of Thyroid Cancer Among the European Union 15+ Countries, 1990-2019

Schuster-Bruce, James; Jani, Chinmay; Goodall, Richard; Kim, Dae; Hughes, William E.; Salciccioli, Justin D.; Marshall, Dominic C; Shalhoub, Joseph

doi:10.1001/jamaoto.2021.4549

Cited by 32 publications

(21 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The trend of rising incidence began to regress first in South Korea in 2014 with a 30% reduction in nodule detection in response to less screening, and as a result, less diagnosis ( 15 ). Similarly, recent findings from the Global Burden of Disease Study found that incidence rates have started to plateau in EU15+ nations and in the US between 2011 and 2019 ( 18 ). However, in low- and middle-income countries, incidence rates have continued to rise ( 19 ).…”

Section: Global Burden Of Thyroid Nodulesmentioning

confidence: 80%

“…One potential driver is clinical concern that the risk of malignancy for pathologically analyzed samples is underestimated ( 50 ). Although thyroid cancer incidence rates have started to plateau in the US after changes in ATA recommendations, disability-adjusted life years have not yet improved which may reflect suboptimal risk stratification and higher average healthcare expenditures relative to other countries ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, in low- and middle-income countries, incidence rates have continued to rise ( 19 ). Although the incidence in high-income countries may be decreasing, overall rates of thyroid cancer are still highest in these countries with the most incident cases in China, the United States, and India ( 18 , 20 ). Further, significant variability in reported rates exists globally.…”

Section: Global Burden Of Thyroid Nodulesmentioning

confidence: 99%

See 2 more Smart Citations

Thyroid nodules: Global, economic, and personal burdens

2023

View full text Add to dashboard Cite

Thyroid nodules have garnered attention due to changes in population surveillance systems and rising concerns about the associated financial burden on healthcare systems, payers, and patients. In this review, we find that prevalence rates vary widely based on method of detection and may particularly pronounced in asymptomatic patients undergoing routine screening. Incidence rates may be particularly rising in lower-income and middle-income countries and may be declining in higher-income countries. Despite high incidence rates, survival rates continue to be as high as 97% for papillary thyroid cancer. Over the last few decades, thyroid nodule workup and management has grown more sophisticated with the advent of fine-needle aspiration biopsy, specialized biomarkers, and molecular testing. However, gaps remain in risk stratification that can lead to substantial costs of care. Certain molecular tests, such as the Afirma Gene Sequencing Classifier can lead to a cost per diagnosis of $17,873 while achieving only mild decreases in diagnostic lobectomies for patients (11.6% to 9.7% in one study). Out-of-pocket costs associated with thyroid nodule management continue to drive significant financial toxicity for patients, especially for individuals with thyroid cancer. Financial toxicity has been defined as a term that describes how direct and indirect medical costs of cancer care strain patients and households via decreased income, assets, and spending on basic necessities. Recent studies suggest that such toxicity can lead to adverse financial outcomes, such as foreclosure and bankruptcy. Additional cost-effectiveness analyses are needed to improve existing thyroid nodule management systems and new clinical tools are needed to avoid unnecessary workup and management.

show abstract

Section: Global Burden Of Thyroid Nodulesmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Global Burden Of Thyroid Nodulesmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid nodules: Global, economic, and personal burdens

2023

View full text Add to dashboard Cite

show abstract

“…According to the researchers' conclusions, the trend toward a decrease in incidence and mortality rates has emerged in all countries except for the United States of America, Australia, and Denmark [11].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Thyroid Cancer Incidence and Mortality Trends Among the Residents of the Sumy Region

Kurochkin¹,

Moskalenko

2022

EUMJ

View full text Add to dashboard Cite

Introduction. Thyroid cancer ranks ninth in the structure of malignant neoplasms. Since the 1980s, most countries in the world have seen a rapid increase in the incidence rate and a relatively stable or even decreasing mortality rate. The objective of our study was to analyze the thyroid cancer morbidity and mortality trends in the Sumy region during 2014–2021, to study the prevalence of histological variants and sex-age-specific characteristics, and to compare them with all-Ukrainian and global data. Study results. According to the National Cancer Registry of Ukraine, 24,626 people were diagnosed with thyroid cancer between 2014 and 2021, including 4,556 men (18.5%) and 2,0070 women (81.5%). On average, 3078.25 ± 136.15 people were diagnosed per year. The incidence rate among women is 3.8 times higher than among men. The average incidence rate in Ukraine in 2014–2021 was 6.5 per 100,000 population, while in the Sumy region – 8.9 per 100,000 population. The average mortality rates among residents of the Sumy region and Ukraine did not differ and amounted to 0.4 per 100,000 population. A distinctive feature was represented by the lower male and higher female mortality rates in the Sumy region compared to all-Ukrainian indicators (0.2 versus 0.3 per 100,000 population and 0.6 versus 0.4 per 100,000 population, respectively). The study of histological types of thyroid malignancies demonstrated that papillary variant was most common (70.5 to 81.9%). The specific share of follicular cancer ranged from 12.8 to 19.2%. The medullary variant occured much less often – in 1.5 to 4.6% of cases, while undifferentiated and squamous cell cancer was extremely rare (0.2 to 3.3% of cases). In Buryn district, Velyka Pysarivka district, Konotop district, Krasnopillia district, Krolevets district, Lebedyn district, Nedrygailiv district, Putyvl district, Sumy district, Trostyanets district and the city of Sumy, a significantly higher incidence rate was observed. Women aged 50–64 and men aged 55–69 are most often affected in Ukraine. The highest mortality rate is reported for the age range of 70–84 years for both males and females. Conclusions. During 2014–2021, the incidence and mortality rates among the population of Ukraine remained at a stable level and were lower compared to global indicators. Since 2017, the Sumy region has been presenting with a decrease in the incidence rate, which corresponds to European trends. In the Sumy region, papillary thyroid cancer remains the most common histological variant. In general, the shares of papillary, follicular, medullary, and anaplastic cancers are consistent with the European figures. In general, the age trends in Ukraine and other countries of the world are similar.

show abstract

“…Eine kürzlich veröffentlichte Erhebung zu Inzidenz, Mortalität und krankheitsbelasteten Lebensjahren in Zusammenhang mit Schilddrüsenkrebs zwischen 1990 und 2019 in Europa, Australien, den USA und Kanada ergab bei gleichbleibenden Inzidenzen in den meisten Ländern eine Abnahme der Mortalität und Krankheitslast im Beobachtungszeitraum. Nur in den USA, Dänemark und Australien waren sowohl altersadjustiert steigende Todesraten als auch krankheitsbelastete Lebensjahre zu beobachten 1 .…”

Section: Epidemiologieunclassified